All In Biotech

Drug Trial Radar · NCT06536491

EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema

A Randomized, Controlled, Subject- and Evaluator-Masked, Phase 2 Clinical Trial Comparing EC-104 Intravitreal Implant to Ozurdex® for the Treatment of Diabetic Macular Edema (BETTIS-1)

Last checked: Nov 20, 2026Latest source record: Sep 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Aug 19, 2024

Primary completion

Oct 15, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Eclipse Life Sciences, Inc.Industry
Sponsor type
Industry
First posted
Aug 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, subject- and evaluator-masked, Phase 2, multicenter study comparing the safety and efficacy of EC-104-6M high-dose (fluocinolone acetonide \[FA\] 0.14 mg) implant and EC-104-4M low-dose (FA 0.092 mg) implant to Ozurdex® (dexamethasone intravitreal (IVT) implant, 0.7 mg) in subjects with diabetic retinopathy (DR) and center-involving diabetic macular edema (DME), with prior suboptimal clinical response to IVT anti-VEGF therapy who have been previously treated with locally administered corticosteroids without a clinically significant rise in intraocular pressure (IOP).

Conditions

  • Diabetic Macular Edema

Interventions

  • EC-104 high doseDrug

    Intravitreal injection

  • EC-104 low doseDrug

    Intravitreal injection

  • Dexamethasone intravitreal implantDrug

    Marketed product intravitreal injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ocular and Systemic SafetyTime frame: Through Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Retina Associates of Florida, LLC

    Tampa, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.